血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay)
ANHU; SERPINA8; Angiotensin; Renin Substrate; Serpin Peptidase Inhibitor,Clade A,Member 8(Alpha-1 Antiproteinase,Antitrypsin)
（注：?jiǎn)未位鞙y(cè)多因子不超過8個(gè)指標(biāo) ）
- 編號(hào)LMA797Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.05-50ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.017 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2562 ¥ 2660 ¥ 2808 ¥ 3005 ¥ 3202 ¥ 3497 ¥ 3941 ¥ 4926 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 99-105 | 102 |
| EDTA plasma(n=5) | 88-96 | 92 |
| heparin plasma(n=5) | 80-92 | 85 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 99-105% | 92-105% | 80-88% | 91-102% |
| EDTA plasma(n=5) | 96-103% | 92-101% | 82-101% | 80-94% |
| heparin plasma(n=5) | 97-105% | 95-103% | 89-102% | 79-91% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA797Ra61 | 血管緊張素原(AGT)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA797Ra01 | 血管緊張素原(AGT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA797Ra61 | 血管緊張素原(AGT)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA797Ra01 | 血管緊張素原(AGT)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA797Ra71 | 血管緊張素原(AGT)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAA797Ra81 | 血管緊張素原(AGT)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| MAA797Ra21 | 血管緊張素原(AGT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA797Ra22 | 血管緊張素原(AGT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA797Ra23 | 血管緊張素原(AGT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA797Ra24 | 血管緊張素原(AGT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA797Ra27 | 血管緊張素原(AGT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA797Ra26 | 血管緊張素原(AGT)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA797Ra | 血管緊張素原(AGT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA797Ra | 血管緊張素原(AGT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA797Ra01 | 血管緊張素原(AGT)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Transplant International | Elevated urinary angiotensinogen a marker of intrarenal renin angiotensin system in hypertensive renal transplant recipients: does it play a role in development of proteinuria in hypertensive renal transplant patients? [Wiley: source] |
| Amyloid | The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients [PubMed: 22320202] |
| Pediatric Mephrology | Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension [PubMed: PMC3661928] |
| Acta Paediatrica | Urinary angiotensinogen as a novel marker of obstructive nephropathy in children [Pubmed: 23772991] |
| Journal of the Renin-Angiotensin-Aldosterone System | Association between urinary angiotensinogen, hypertension and proteinuria in pregnant women with preeclampsia [Sagepub: Source] |
| Pediatric Nephrology | MP707 CHARACTERISTICS AND OUTCOMES OF CHILDREN WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE COHORT FROM THE ESPN/ERA-EDTA REGISTRY [Oxfordjournals:Source] |
| journal of human hypertension | Relationship between blood pressure var [PubMed: 26223347] |
| PLoS One | Higher Serum Angiotensinogen Is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes Analysis [PubMed: 26098644] |
| MKA | Korelasi pengukuran antropometri dengan tekanan darah dan angiotensinogen plasma pada dewasa [Index.Php: Art] |
| Journal of Human Hypertension | Relationship between blood pressure variability and renal activity of the renin-angiotensin system. [pubmed:26223347] |
| Acta Pharmacol Sin. | Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells. [pubmed:27890915] |
| Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis [S0021967317311858] |
| Life?Sciences | Pyrrolidine dithiocarbamate inhibits mouse acute kidney injury induced by diclofenac by targeting oxidative damage, cytokines and NF-κB activity [Pubmed:30036488] |
| American Journal of Physiology-Renal?Physiology | Role of (Pro) Renin Receptor in Albumin Overload-Induced Nephropathy in Rats [Pubmed:29846109] |
| Methods in Molecular Biology | Quantitation of Total and Free Thiol Angiotensinogen as a Prognostic Marker for Preeclampsia [Pubmed: 31069778] |
| J Transl Med | Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans [33407555] |
| Hypertens Res | Association of Ang-(1¨C7) and des-Arg 9 BK as new biomarkers of obesity and cardiometabolic risk factors in adolescents [33568792] |
| Physiol Rep | (Pro) renin receptor antagonist PRO20 attenuates nephrectomy?\induced nephropathy in rats via inhibition of intrarenal RAS and Wnt/|??\catenin signaling [34057312] |
| Cancer Cell Int | A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer [34215253] |
